Proteinase inhibitors: a promising drug class for treating leishmaniasis

Curr Drug Targets. 2014;15(12):1121-31. doi: 10.2174/1389450115666141016150007.

Abstract

This review presents and discusses the current status and perspectives of leishmaniasis treatment, with a special focus on the use of proteinase inhibitors. The history of treatment development, the first- and second-choice modern drugs and the advantages and disadvantages of using proteinases inhibitors as leishmanicidal treatments are presented and discussed. The reports gathered herein confirm the potential usefulness of proteinases inhibitors as an alternative or complement to the current leishmaniasis treatments. They also support the hypothesis that a combined treatment with multiple proteinase inhibitors may be efficient against Leishmania infections in vertebrate hosts.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antiprotozoal Agents / administration & dosage*
  • Antiprotozoal Agents / pharmacology
  • Cysteine Proteinase Inhibitors / administration & dosage*
  • Cysteine Proteinase Inhibitors / pharmacology
  • Drug Therapy, Combination
  • Humans
  • Leishmaniasis / drug therapy*

Substances

  • Antiprotozoal Agents
  • Cysteine Proteinase Inhibitors